Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TPST2 | O60704 | 2/20 | 0.35 |
| ▸ | SULT1E1 | P49888 | 2/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 2/20 | 0.34 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
| ▸ | S100A9 | P06702 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7023548 | 0.80 | PTPN1 (0.39) | PTPN1GPR35PDE10AKMT2AALDH1A1 | |
| SCHEMBL7026584 | 0.79 | PTPN1 (0.64) | PTPN1GPR35KMT2AALDH1A1POLB | |
| SCHEMBL28346097 | 0.77 | PTPN1 (0.52) | PTPN1GPR35PDE10AKMT2AMEN1 | |
| SCHEMBL8171800 | 0.75 | PTPN1 (0.61) | PTPN1PDE10AKMT2AALDH1A1MEN1 | |
| SCHEMBL10991271 | 0.74 | PTPN1 (0.56) | PTPN1GPR35KMT2AALDH1A1POLB | |
| SCHEMBL5708656 | 0.72 | PTPN1 (1.00) | PTPN1PDE10AKMT2APOLBTDP1 | |
| SCHEMBL11541084 | 0.72 | PTPN1 (0.58) | PTPN1PDE10AKMT2AALDH1A1POLB | |
| SCHEMBL11262105 | 0.71 | PTPN1 (0.56) | PTPN1GPR35PDE10AKMT2AALDH1A1 | |
| SCHEMBL31619653 | 0.71 | GPR35 (0.45) | PTPN1GPR35KMT2AALDH1A1POLB | |
| SCHEMBL11551282 | 0.71 | ALDH1A1 (0.59) | KMT2AALDH1A1POLBTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872029-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP | 2011-01-18 | — | — | US | disclosed |
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Robinson, Thomas Philip (US) | 2009-01-15 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-7432303-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | Bowen, J. Phillip (US) | 2008-10-07 | — | — | US | disclosed |
| US-6906105-B2 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN J PHILLIP (US) | 2005-06-14 | — | — | US | disclosed |
| US-6462075-B1 | USE OF CHALCONE AND ITS DERIVATIVES AS ANTITUMOR/ANTICANCER AGENTS AND TO TREAT A NUMBER OF CONDITIONS OR DISEASE STATES IN WHICH ANGIOGENESIS IS A FACTOR INCLUDING PSORIASIS, ACNE, ROSACEA, WARTS, ECZEMA, HEMANGIOMAS AND LYMPHANGIOGENESIS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2002-10-08 | — | — | US | disclosed |
| US-4320133-A | Penicillins and their antibacterial use | SANDOZ LTD. (CH) | 1982-03-16 | — | — | US | disclosed |
| EP-0003115-A1 | Penicillins, per se and for use as antibacterially active antibiotics and their production | SANDOZ AG (CH) | 1979-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018167-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | PTPN1 837/4885GPR35 2823/4885PDE10A 4389/4885 |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | CCNK, CDK3, CCNO | PTPN1 3779/4885GPR35 3453/4885PDE10A 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.